Seven potential blockbusters set to launch in 2016; Amarin case may lead to ‘misleading’ marketing; Valeant, Turing raised prices to meet preset targets
The FDA declines to approve two drugs for Duchenne muscular dystrophy; government watchdog questions FDA’s post-market drug tracking; WebMD denies acquisition talks
Five things for pharma marketers to know: Monday, January 4, 2016
FDA advisers vote against BioMarin’s Duchenne drug; the FDA approves Lilly’s lung-cancer drug; criticism mounts for Pfizer’s proposed deal with Allergan
Five things for pharma marketers to know: Tuesday, November 24, 2015
Opdivo receives another indication; increasing generic prescriptions may boost patient adherence; hep.-C drugs should be prescribed during earlier stages of disease